While it is well-appreciated that ERBB2 (HER2) gene amplification and protein expression is a bona fide therapeutic target in the treatment of patients with breast and gastric cancers, more recent trials have drawn attention to its actionability in other cancer types (23, 24). This evidence concerns the gene ERBB2 and gastric cancer.